<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04919499</url>
  </required_header>
  <id_info>
    <org_study_id>1451-0001</org_study_id>
    <nct_id>NCT04919499</nct_id>
  </id_info>
  <brief_title>A Study of BI 765128 in Patients With an Eye Condition Called Diabetic Macular Ischemia Who Have Received Laser Treatment</brief_title>
  <acronym>PARTRIDGE</acronym>
  <official_title>A First in Human Trial to Study Safety and Tolerability of Single Rising Intravitreal Doses (oPen Label, Non-randomized, Uncontrolled) and in Addition the Early Biological Response of mulTiple Intravitreal Doses (Double-masked, RandomIzed, Sham-controlleD) of BI 765128 in Panretinal photocoaGulation (PRP) Treated Diabetic rEtinopathy (DR) Patients With Diabetic Macular Ischemia (DMI) - the PARTRIDGE Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is open to adults with diabetic macular ischemia who have received laser&#xD;
      treatment. The main purpose of this study is to find out whether people with diabetic macular&#xD;
      ischemia can tolerate a medicine called BI 765128.&#xD;
&#xD;
      In this study, BI 765128 is given to people for the first time.&#xD;
&#xD;
      The study has 2 parts. Part A tests 3 doses of BI 765128. Participants get either a low,&#xD;
      medium or high dose of BI 765128 as a single injection into the eye. If participants tolerate&#xD;
      it well, the highest dose will be used in part B.&#xD;
&#xD;
      In part B, participants are put into 2 groups randomly, which means by chance. 1 group gets&#xD;
      BI 765128 as injection into the eye. The other group gets sham injections. A sham injection&#xD;
      means that it is not a real injection and contains no medicine. Participants cannot tell&#xD;
      whether they get the real injection or a sham injection. In this part, participants receive&#xD;
      study treatment once every month for 3 months.&#xD;
&#xD;
      Participants in part A are in the study for about 4 months and visit the study site about 8&#xD;
      times.&#xD;
&#xD;
      Participants in part B are in the study for about 5 months and visit the study site about 7&#xD;
      times.&#xD;
&#xD;
      The doctors regularly check participants' health and take note of any unwanted effects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 30, 2021</start_date>
  <completion_date type="Anticipated">June 5, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 5, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Description to masking:&#xD;
In Part A no masking will be performed. In Part B participant and investigator will be masked.&#xD;
Description to randomisation:&#xD;
In Part A no randomisation will be performed. In Part B randomisation will be performed.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Part A: Number of subjects with ocular dose limiting events (DLEs) from drug administration until day 8 (7 days after treatment)</measure>
    <time_frame>up to 7 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Number of subjects with drug related Adverse Events (AEs) from drug administration until end of study (EOS)</measure>
    <time_frame>up to 20 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part A: Number of subjects with drug related Adverse Events (AEs) at end of study (EOS)</measure>
    <time_frame>up to 14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Number of subjects with any ocular Adverse Events (AEs) (eye disorders) at end of study (EOS)</measure>
    <time_frame>up to 14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Change from baseline of the size of the foveal avascular zone (FAZ) in optical coherence tomography angiography (OCTA) at visit 5</measure>
    <time_frame>up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Change from baseline of the size of the foveal avascular zone (FAZ) in optical coherence tomography angiography (OCTA) at visit 6</measure>
    <time_frame>up to 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Change from baseline of the size of the foveal avascular zone (FAZ) in optical coherence tomography angiography (OCTA) at visit 7</measure>
    <time_frame>up to 20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Change from baseline of best corrected visual acuity (BCVA) at Visit 7</measure>
    <time_frame>up to 20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Number of subjects with any ocular Adverse Events (AEs) (eye disorders) from drug administration until end of study (EOS)</measure>
    <time_frame>up to 20 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Diabetic Retinopathy</condition>
  <arm_group>
    <arm_group_label>Part A: BI 765128 low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: BI 765128 medium dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: BI 765128 high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: BI 765128</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Highest safe dose from Part A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Sham comparator</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 765128</intervention_name>
    <description>BI 765128</description>
    <arm_group_label>Part A: BI 765128 high dose</arm_group_label>
    <arm_group_label>Part A: BI 765128 low dose</arm_group_label>
    <arm_group_label>Part A: BI 765128 medium dose</arm_group_label>
    <arm_group_label>Part B: BI 765128</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sham comparator</intervention_name>
    <description>Sham comparator</description>
    <arm_group_label>Part B: Sham comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Part A:&#xD;
&#xD;
          -  Panretinal photocoagulation-treated diabetic retinopathy (DR) patients with either no&#xD;
             or inactive retinal neovascularization per investigator judgement in the study eye&#xD;
&#xD;
          -  Male or female subjects of age ≥ 18 years&#xD;
&#xD;
          -  Evidence of diabetic macular ischemia (DMI) per investigator´s judgement, defined as&#xD;
             any degree of disruption of retinal vascularity in optical coherent tomography&#xD;
             angiography (OCTA)&#xD;
&#xD;
          -  Glycosylated Hemoglobin, Type A1C (HbA1c) of ≤ 12.0%&#xD;
&#xD;
          -  Best-corrected visual acuity (VA) ≤65 letters (20/50) in the study eye&#xD;
&#xD;
          -  Best corrected visual acuity (VA) in the non-study eye must be equal to or better than&#xD;
             best corrected VA in the study eye. If both eyes are eligible and have identical best&#xD;
             corrected VA the investigator may select the study eye.&#xD;
&#xD;
          -  Women of childbearing potential (WOCBP) and men able to father a child must be ready&#xD;
             and able to use two methods of contraception with at least one of them being a highly&#xD;
             effective method of birth control per ICH M3 (R2) that result in a low failure rate of&#xD;
             less than 1% per year when used consistently and correctly.&#xD;
&#xD;
          -  Signed and dated written informed consent in accordance with ICH GCP Harmonized&#xD;
             Guideline for Good Clinical Practice and local legislation prior to admission to the&#xD;
             trial&#xD;
&#xD;
        Part B:&#xD;
&#xD;
          -  Panretinal photocoagulation-treated diabetic retinopathy (DR) patients with either no&#xD;
             or inactive retinal neovascularization per investigator judgement&#xD;
&#xD;
          -  Male or female subjects of age ≥ 18 years&#xD;
&#xD;
          -  Presence of significant diabetic macular ischemia (DMI): Large foveal avascular zone&#xD;
             (FAZ) defined as those with ≥0.5mm2 area present on optical coherent tomography&#xD;
             angiography (OCTA). If FAZ is &lt;0.5mm2 then an enlarged peri-foveal inter-capillary&#xD;
             space in at least 1 quadrant will be sufficient.&#xD;
&#xD;
          -  Glycosylated Hemoglobin, Type A1C (HbA1c) of ≤ 12.0%&#xD;
&#xD;
          -  Best-corrected visual acuity (VA) ≤80 letters (20/25) in the study eye&#xD;
&#xD;
          -  Best-corrected visual acuity (VA) in the non-study eye must be equal to or better than&#xD;
             best-corrected VA in the study eye. If both eyes are eligible and have identical best&#xD;
             corrected VA, the investigator may select the study eye.&#xD;
&#xD;
          -  Women of childbearing potential (WOCBP) and men able to father a child must be ready&#xD;
             and able to use two methods of contraception with at least one of them being a highly&#xD;
             effective method of birth control per ICH M3 (R2) that result in a low failure rate of&#xD;
             less than 1% per year when used consistently and correctly.&#xD;
&#xD;
          -  Signed and dated written informed consent in accordance with ICH GCP Harmonized&#xD;
             Guideline for Good Clinical Practice and local legislation prior to admission to the&#xD;
             trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Part A:&#xD;
&#xD;
          -  Subjects receiving intravitreal (IVT) injections for active Diabetic Macular Edema&#xD;
             (DME) (anti-vascular endothelial growth factor (VEGF), steroids) and macular laser in&#xD;
             the previous 6 months to screening in the study eye&#xD;
&#xD;
          -  Subjects receiving anti-VEGF IVT injections for active diabetic retinopathy (DR) in&#xD;
             the previous 6 months to screening in the study eye&#xD;
&#xD;
          -  Current or planned use of medications known to be toxic to the retina, lens or optic&#xD;
             nerve (e.g. desferoxamine, chloroquine/hydrochloroquine, chlorpromazine,&#xD;
             phenothiazines, tamoxifen, nicotinic acid, and ethambutol)&#xD;
&#xD;
          -  Additional progressive eye disease in the study eye that could compromise best&#xD;
             corrected visual acuity (VA) (best corrected visual acuity (BCVA)), uncontrolled&#xD;
             glaucoma (intra-ocular pressure (IOP)&gt;24), history of high myopia &gt; 8 diopters in the&#xD;
             study eye. Anterior segment and vitreous abnormalities in the study eye that would&#xD;
             preclude adequate observation with spectral domain optical coherence tomography&#xD;
             (SD-OCT) and optical coherent tomography angiography (OCTA).&#xD;
&#xD;
          -  Any intraocular surgery in the study eye within 3 months prior to screening&#xD;
&#xD;
          -  Glaucoma tube shunts&#xD;
&#xD;
          -  Aphakia or total absence of the posterior capsule. Yttrium aluminum garnet (YAG) laser&#xD;
             capsulotomy permitted, if completed more than 3 months prior to screening, in the&#xD;
             study eye&#xD;
&#xD;
          -  Subjects not expected to comply with the protocol requirements or not expected to&#xD;
             complete the trial as scheduled (e.g. chronic alcohol or drug abuse or any other&#xD;
             condition that, in the investigator´s opinion, makes the subject an unreliable trial&#xD;
             subject) Further exclusion criteria apply&#xD;
&#xD;
        Part B:&#xD;
&#xD;
          -  Diabetic Macular Edema (DME), defined as a Central Subfield Thickness (CST) ≥ 305μm&#xD;
             for men and ≥ 290 μm for women (Optovue Angiovue) in the study eye&#xD;
&#xD;
          -  Subjects receiving intravitreal (IVT) injections for active DME (anti-vascular&#xD;
             endothelial growth factor (VEGF), steroids) and macular laser in the previous 6 months&#xD;
             to screening in the study eye&#xD;
&#xD;
          -  Subjects receiving anti-VEGF intravitreal IVT injections for active Diabetic&#xD;
             Retinopathy (DR) in the previous 6 months to screening in the study eye&#xD;
&#xD;
          -  Heavily lasered macula in the study eye per investigator judgement&#xD;
&#xD;
          -  History of vitrectomy in the study eye&#xD;
&#xD;
          -  Epiretinal membrane with extended foveal contour distortion in the study eye&#xD;
&#xD;
          -  Clinically significant disorganisation of retinal inner layer (DRIL) in the study eye&#xD;
&#xD;
          -  Current or planned use of medications known to be toxic to the retina, lens or optic&#xD;
             nerve (e.g. desferoxamine, chloroquine/hydrochloroquine, chlorpromazine,&#xD;
             phenothiazines, tamoxifen, nicotinic acid, and ethambutol) Further exclusion criteria&#xD;
             apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Boehringer Ingelheim</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Bay Area Retina Associates - Walnut Creek</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caesar Luo</last_name>
      <phone>+001(925)943-6800</phone>
      <email>cluo@bayarearetina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Austin Research Center for Retina, PLLC</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chirag Jhaveri</last_name>
      <phone>+001(512)279-1251</phone>
      <email>cjhaveri@e-retina.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bristol Eye Hospital</name>
      <address>
        <city>Bristol</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clare Bailey</last_name>
      <phone>01179230060</phone>
      <email>Clare.Bailey@uhbw.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Liverpool University Hospital</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simon Harding</last_name>
      <phone>+441517062000</phone>
      <email>Simon.harding@liverpoolft.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Moorfields Eye Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sobha Sivaprasad</last_name>
      <phone>02075662117</phone>
      <email>Sobha.sivaprasad@nhs.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oxford Eye Hospital</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Kiire</last_name>
      <email>Christine.Kiire@ouh.nhs.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mystudywindow.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 8, 2021</study_first_submitted>
  <study_first_submitted_qc>June 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2021</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions:&#xD;
studies in products where Boehringer Ingelheim is not the license holder;&#xD;
studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials;&#xD;
studies conducted in a single center or targeting rare diseases (because of limitations with anonymization).&#xD;
For more details refer to: https://www.mystudywindow.com/msw/datasharing</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

